Company intelligence / Profile preview

StarWise Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

StarWise Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation RNA interference (RNAi) therapies. The company's primary mission is to enable the delivery of small interfering RNA (siRNA) to tissues outside of the liver, such as the central nervous system, lungs, and muscle. Leveraging a proprietary delivery platform, StarWise aims to expand the therapeutic potential of RNAi to a wider array of genetic and chronic diseases. The leadership team includes veterans from Alnylam Pharmaceuticals and Third Rock Ventures, bringing significant expertise in RNA medicine and drug development.

Therapeutic areas: RheumatologyPulmonologyNeurology
Modalities: Small interfering RNARNA therapy
Industry: Biotech

Beyond the preview

Go deeper on StarWise Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StarWise Therapeutics.

Explore the full profile